To receive all of the company’s financial communications in real time, please register directly by email at the following address: [email protected]
Berlin, Germany, July 15, 2022, 6:00 p.m. CEST – TME Pharma NV, a biotechnology company specializing in the development of novel therapies for the treatment of cancer by targeting the tumor microenvironment (MET), today announces that it has entered into a transaction with Atlas Special Opportunities, LLC (ASO), for a total amount of 3.24 million euros. The transaction will be completed in two tranches over the next two months. Following the transaction, the company will issue 3,300 convertible bonds (including 60 convertible bonds issued in connection with the transaction costs) with a nominal value of 1,000 euros each.